BioPharm简报:FDA细胞与基因治疗效价保证最终指南、Lonza收购默克美国CDMO业务、Tiziana鼻用抗体foralumab治疗进展型MS的2a期数据
The BioPharm Brief: A Potency Rulebook, a CDMO Buyout, and a Nasal Antibody for MS
FDA发布细胞与基因治疗效价保证最终指南,取代2011年效价检测指南,要求从IND到上市后全程采用基于风险的效价保证策略,并计划12月10日举办网络研讨会。Lonza同意收购默克KGaA美国CDMO业务,新增5个站点和约1100名员工,交易预计2027年年中完成。
Today’s BioPharm Brief covers FDA’s final potency assurance guidance for cell and gene therapies, Lonza’s deal to acquire Merck KGaA’s US CDMO business, and Phase 2a data for Tiziana’s intranasal anti-CD3 antibody foralumab in progressive multiple sclerosis.
Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry. Today, we’re looking at new FDA expectations for cell and gene therapy potency, a major expansion of US manufacturing capacity, and mixed results for a nasal antibody in progressive MS.
First, FDA has finalized its guidance on potency assurance for cell and gene therapy products. It replaces the agency’s 2011 guidance on potency testing. Instead of treating potency as a single release test, FDA wants manufacturers to follow a risk-based potency assurance strategy across the full product lifecycle, from early IND submissions through BLA approval and postmarket verification. That strategy covers raw material variability, in-process testing, and assays confirming biological activity. The guidance also has dedicated sections on short-shelf-life products, viral vector gene therapies, and patient-specific therapies. FDA plans a webinar on December 10 to support implementation.
Next, Lonza has agreed to acquire Merck KGaA’s US contract development and manufacturing business. The deal brings in five sites and about 1,100 employees. The sites cover bioconjugation in St. Louis, high-potency ADC payload-linkers in Wisconsin, viral vector manufacturing in Carlsbad, California, and lipid nanoparticle and liposome production in Indianapolis. It takes Lonza’s US footprint from four sites to nine and fills a US bioconjugation gap the company flagged just weeks ago. The deal is expected to close in mid-2027, pending regulatory approvals.
And, Tiziana Life Sciences reported Phase 2a results for foralumab, a fully human anti-CD3 monoclonal antibody given as a nasal spray, in non-active secondary progressive MS. In the 48-patient INFORM-MS trial, the 50-microgram dose significantly reduced microglial activation in white matter on PET imaging compared with placebo. The 100-microgram dose did not reach statistical significance on that endpoint. No serious adverse events were related to the study drug. The nasal route is designed to stimulate regulatory T cells rather than broadly suppress the immune system. Tiziana plans to meet with FDA to discuss next steps.
That’s today’s BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.
Key takeaways
- Potency over the full lifecycle: FDA’s final guidance expects cell and gene therapy developers to build potency assurance from IND through postmarket, not just test at release.
- US capacity consolidation: Lonza’s purchase of Merck KGaA’s US CDMO business more than doubles its US network, adding ADC, viral vector, and LNP capabilities.
- A dose puzzle in progressive MS: Low-dose intranasal foralumab reduced brain inflammation on PET imaging, but the higher dose missed, which raises questions about the dose-response.
Related to this article
October 30th, 2026
FDA approves Sun Pharma’s Ilumya for active psoriatic arthritis, BioMarin licenses a subcutaneous Fabry enzyme replacement therapy from GC Biopharma and Hanmi, and Lonza expands bioconjugation capacity in Visp to meet rising ADC demand.
October 28th, 2026
Genmab’s petosemtamab plus pembrolizumab cuts the risk of death by 50% in phase 3 head and neck cancer, AbbVie submits a BLA for etentamig in relapsed or refractory multiple myeloma, and Benitec reports interim data for BB-301 gene therapy in OPMD-related dysphagia.
October 27th, 2026
BMS and SystImmune’s bispecific ADC iza-bren nearly doubles progression-free survival in EGFR-mutated lung cancer, GSK and Hansoh’s B7-H3 ADC Ris-Rez extends progression-free survival in relapsed osteosarcoma, and Immatics’ TCR bispecific IMA402 posts a 32% response rate in PRAME-high tumors.
November 3rd, 2026
At AAPS PharmSci 360 2026, University of Iowa PhD candidate Siddhanth Hejmady explains how adding a payload or radiolabel to trastuzumab changes its behavior in bulk solution and at interfaces, and why developability teams should pair DLS with QCM-D.
November 3rd, 2026
In the Phase 2a INFORM-MS trial, Tiziana’s nasal foralumab reduced microglial activation on PET imaging at 50 µg in non-active secondary progressive MS, while the 100-µg dose showed no significant effect.
November 3rd, 2026
The deal adds five US sites and about 1,100 employees, more than doubling Lonza’s US network and filling a gap in US bioconjugation capacity the company flagged weeks earlier.
November 2nd, 2026
AAPS PharmSci 360 2026 in New Orleans centered on auditable AI, modeling-guided formulation, oral peptide delivery, high-concentration antibody suspensions, and the push toward $10-per-gram monoclonal antibodies.
November 2nd, 2026
The deal gives Fresenius options on biosimilars spanning monoclonal and bispecific antibodies, ADCs, and fusion proteins, starting with polatuzumab vedotin and teprotumumab, and could expand its portfolio from 29 to 66 molecules.
来源:BioPharm International · biopharminternational.com





